Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

49.940
+0.7201.46%
Volume:29.99M
Turnover:1.50B
Market Cap:207.55B
PE:36.78
High:50.950
Open:49.900
Low:49.420
Close:49.220
52wk High:54.450
52wk Low:28.480
Shares:4.16B
HK Float Shares:4.16B
Volume Ratio:1.09
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.358
ROE:11.38%
ROA:7.60%
PB:3.69
PE(LYR):36.78
PS:7.51

Loading ...

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis

Stock News
·
Aug 25

WuXi Bio Posts Robust H1 2026: Revenue Hits RMB 11.79 Billion, Adjusted Gross Margin Widens to 48.4%; Raises FY Growth Guidance

Bulletin Express
·
Aug 25

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Aug 25

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS
·
Aug 25

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

Dow Jones
·
Aug 25

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Reuters
·
Aug 25

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Aug 25

Movement Alert|WUXI BIO Rises 3.81% in Regular Trading, Interim Results Review Coincides with CXO Sector Broad Rally

Market Focus
·
Aug 25

Transcenta Holding Announces Extraordinary General Meeting

Reuters
·
Aug 25

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

Reuters
·
Aug 24

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Reuters
·
Aug 24

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Dow Jones
·
Aug 24

Movement Alert|WUXI BIO Falls 3.33% in Regular Trading, CXO Sector Pullback and Pre-Earnings Profit-Taking Weigh on Shares

Market Focus
·
Aug 24

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

Reuters
·
Aug 21

Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong

Dow Jones
·
Aug 21